Cancer Biomarkers: A Guide to Testing, Results and Treatment Decisions

A biomarker is a measurable biological feature. In cancer care, some biomarkers help identify a cancer, while others provide information about its likely behavior or possible treatment sensitivity. Biomarker testing for treatment selection may also be called tumor profiling, molecular testing or genomic testing. These names overlap, but they do not necessarily mean that the same genes, proteins or methods were examined.

Predictive and prognostic results answer different questions. A predictive biomarker helps estimate whether a particular treatment is likely to benefit someone with that cancer. A prognostic biomarker provides information about the likely course of the disease. A result can have both roles, but neither should be interpreted independently of the cancer type, stage and other clinical findings.

A useful result may point toward targeted therapy or immunotherapy, or away from a treatment unlikely to work. It may also identify a research opportunity. Testing cannot always find a treatable feature, and cancers with the same biomarker do not always respond alike. Ask which clinical question the proposed test is intended to answer and what decisions could change.

Testing may be relevant at diagnosis, before a treatment decision, or when cancer returns or progresses. It is important in certain advanced cancers, but it is not restricted to metastatic disease. Some findings also affect treatment decisions in earlier-stage cancer. The appropriate timing and scope depend on the diagnosis and the question being addressed.

Before testing, ask which biomarkers are recommended for this cancer and whether they have already been examined. A pathology report may contain some results, while a separate molecular report contains others. Clarify whether a focused test or a broader panel is proposed. More genes do not automatically mean a better test: the method must reliably detect the relevant changes, and some necessary protein tests are separate.

Ask whether enough stored tissue is available, when results are expected and how they could affect the planned treatment. If treatment is urgent, the team should explain whether waiting is appropriate or whether care should start while testing continues. Do not postpone or stop treatment independently to obtain a panel. Keep copies of pathology, molecular reports and treatment records for future consultations.

Tissue testing uses material collected during a biopsy or surgery. It allows laboratory specialists to examine cancer cells and test their molecular features. Sometimes the sample contains too few cancer cells, has deteriorated or has already been used for other tests. An insufficient sample is a testing limitation, not a negative biomarker result. The team may consider another stored sample or a new biopsy.

A liquid biopsy usually examines blood for material released by cancer, such as circulating tumor DNA. It can be useful when obtaining tissue is difficult or when looking for certain changes after treatment. However, not all tumors release enough DNA into blood to be detected. A negative blood result may need follow-up with tissue testing and does not establish that no relevant alteration exists.

Different techniques measure different things. Immunohistochemistry, or IHC, examines proteins. Fluorescence in situ hybridization, or FISH, examines selected gene changes. PCR tests selected DNA features, while next-generation sequencing, or NGS, can examine many alterations together. These methods are not interchangeable. Ask whether the chosen approach covers the relevant mutations, gene fusions, copy-number changes or protein expression for this diagnosis.

Start with the sample location, collection date, test method and whether analysis was successful. Then identify the exact finding, its interpretation and the report's limitations. A gene name alone is incomplete: the particular alteration may determine its relevance. Distinguish a detected alteration from a suggested treatment association, especially if that association comes from research in another cancer type.

Read the biomarker report alongside pathology and staging information. Benign means noncancerous; malignant means cancerous. A suspicious molecular finding alone does not replace the diagnostic assessment. Stage describes the extent of cancer, whereas grade describes how abnormal cancer cells appear under the microscope. A high grade is not the same as an advanced stage. Localized cancer remains at its starting site; metastatic cancer has spread to distant sites. Biomarker results do not establish that extent by themselves.

Treatment terminology explains the setting in which evidence applies. Neoadjuvant treatment is given before the main treatment, often surgery; adjuvant treatment follows it to reduce recurrence risk. Response means improvement with treatment, while remission means signs and symptoms have decreased or disappeared. Neither necessarily means cure. When a report lists a drug, ask whether the supporting evidence matches the cancer type, stage and treatment setting.

Gene alterations are not interchangeable. In non-small cell lung cancer, specific EGFR mutations or ALK fusions can guide targeted treatment. Different EGFR alterations may require different approaches. With KRAS, the precise variant and cancer type matter; a result labeled only KRAS-positive is not enough to choose a drug. Some biomarkers predict resistance rather than sensitivity to a proposed treatment.

HER2 testing can assess protein expression or changes involving the HER2 gene. These findings are related but are not equivalent. Terms such as HER2-positive, HER2-low and HER2-ultralow have treatment implications in particular settings, not universally across cancers. The laboratory score, testing method, cancer type and current treatment criteria all need to be considered.

PD-L1 testing measures protein expression using scoring systems such as TPS or CPS. These scores are not interchangeable, and a high result does not guarantee that immunotherapy will work. MSI-high and deficient mismatch repair, or dMMR, describe related abnormalities in DNA repair that may support immunotherapy in eligible settings. A low or negative result on one immunotherapy biomarker does not settle every immunotherapy decision. The treating team must integrate the full diagnosis and other relevant findings.

Tumor testing primarily asks which features of an existing cancer may help guide care. Hereditary-risk testing asks whether someone carries an inherited, or germline, variant associated with cancer risk. Many changes found in tumors are somatic: they developed during life rather than being inherited. A tumor finding alone usually cannot establish whether relatives share an increased risk.

BRCA1 and BRCA2 illustrate the distinction. A clinically important variant can occur only in the tumor or can be inherited. Tumor testing may inform treatment, while a separate germline test can clarify inherited risk. Likewise, some MSI-high or dMMR findings prompt evaluation for Lynch syndrome, but they do not by themselves diagnose an inherited syndrome.

Ask whether a result warrants referral to a genetics professional and whether confirmatory testing is needed. A blood sample is not automatically a hereditary test: blood can also be used for a liquid biopsy looking for tumor DNA. Before germline testing, discuss possible implications for relatives, privacy and follow-up. A variant of uncertain significance should not be treated as a confirmed inherited cancer-risk variant.

A negative result means the test did not identify the feature it was designed to detect within its technical limits. It does not mean there is no cancer or that every possible biomarker was examined. Review what the assay covered, whether the sample was adequate and whether complementary tests remain necessary. An inconclusive or failed test should not be interpreted as a true negative.

A variant of uncertain significance, often abbreviated VUS, is a change whose meaning is not established. It is not a proven treatment target. Reports may also list findings supported only by laboratory research or limited clinical evidence. Ask which findings are established for this cancer, which are investigational and whether any currently change management.

Cancers can contain different cell populations, and their molecular features may change over time or under treatment pressure. Resistance can develop even after an initial response. Repeat tissue or blood testing sometimes helps explain progression and identify another option, but it is not automatically useful at every visit. Ask what decision a repeat test would inform and whether its potential benefit justifies another procedure.

An actionable result is one that may support a clinical decision, but the word does not guarantee access to an effective medicine. A report may list an approved treatment, a drug approved for another cancer or an experimental approach. Ask which category applies, how strong the evidence is and whether the option fits prior treatment, general health and the goals of care.

Clinical trials are not only a last resort. A trial may be worth discussing at diagnosis or at a later treatment decision. Biomarker-selected trials may enroll people with a particular alteration, sometimes across several cancer types. However, having the biomarker is only one requirement. Eligibility, an available place and the suitability of the study must be confirmed directly with the study team.

Discuss likely benefits, known risks, alternatives and required monitoring before choosing any treatment. Targeted therapies and immunotherapies can cause serious side effects; targeted does not mean harmless. Follow the team's urgent-contact instructions. During treatment, fever or signs of infection, new breathing difficulty, severe diarrhea or rapidly worsening symptoms need prompt medical assessment. Severe chest pain, major breathing difficulty or sudden neurological symptoms require emergency care.

Prepare for the results appointment by gathering the complete report, pathology diagnosis, stage information and treatment history. Ask the clinician to separate findings that change care now from findings that might matter later. Request a clear explanation of any missing tests, uncertain results or differences between reports. Confirm who will arrange follow-up and communicate the final interpretation.

When comparing centers, focus on relevant cancer expertise and verified services rather than brand recognition or unverified trial counts. Useful questions include whether specialist pathology review is available, whether the required testing can be performed reliably and whether complex results can receive multidisciplinary molecular review. Confirm access to genetic counseling when inherited risk is a concern.

For a second opinion or trial assessment, check what records and tissue are needed before arranging a visit. Verify whether a specific study is open, accepting patients and relevant to the actual alteration and treatment history. A useful consultation should explain both options and limitations. If no matched therapy is available, ask how standard treatments and appropriate research options fit the overall care plan.